Sector revisions Summit Therapeutics Inc.

Equities

Real-time Estimate Cboe BZX Other stock markets 18:18:14 10/02/2026 GMT			5-day change	1st Jan Change
15.38 ^USD	+2.77%		+5.72%	-11.81%

01-29	Sector Update: Health Care Stocks Edge Higher Premarket Thursday	MT
01-29	Summit Therapeutics Announces U.S. FDA Acceptance of Biologics License Application Seeking Approval for Ivonescimab in Combination with Chemotherapy in Treatment of Patients with EGFRm NSCLC Post-TKI Therapy	CI

Add to a list 0 selected To use this feature you must be a member Log in Sign up	1y. EPS revision	1y. Revenue rev.	Visibility	Nbr of analysts
SUMMIT THERAPEUTICS INC.				13
ARGENX SE				15
WUXI APPTEC CO., LTD.				18
INSMED INCORPORATED				20
BIONTECH SE				19
WUXI BIOLOGICS (CAYMAN) INC.				23
GENMAB A/S				13
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.				17
AKESO, INC.				21
EXELIXIS, INC.				18
MADRIGAL PHARMACEUTICALS, INC.				15
SAMSUNG EPIS HOLDINGS CO., LTD.	-	-	-	1
ARROWHEAD PHARMACEUTICALS, INC.				12
PHARMAESSENTIA CORPORATION				6
VAXCYTE, INC.				9
NUVALENT, INC.				17
CYTOKINETICS, INCORPORATED				18
REMEGEN CO., LTD.				15
BELITE BIO, INC				8
Average				15
Weighted average by Cap.				16